$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-K Financial Statement

#000082787116000049 Filed on February 29, 2016

Income Statement

Concept	2015 Q4	2015	2014 Q4
Revenue	$18.18M	$66.23M	$5.600M
YoY Change	224.64%	246.76%	1.97%
Cost Of Revenue	$2.600M	$15.65M	$1.782M
YoY Change	45.9%	33.58%	-33.26%
Gross Profit	$15.58M	$50.58M	$3.818M
YoY Change	308.07%	584.9%	35.29%
Gross Profit Margin	85.7%	76.37%	68.18%
Selling, General & Admin	$5.610M	$20.17M	$3.690M
YoY Change	52.03%	116.22%	174.55%
% of Gross Profit	36.01%	39.87%	96.65%
Research & Development	$8.780M	$27.86M	$3.986M
YoY Change	120.27%	65.65%	53.96%
% of Gross Profit	56.35%	55.07%	104.4%
Depreciation & Amortization	$80.00K	$112.0K	$13.00K
YoY Change	515.38%	7.69%	-56.67%
% of Gross Profit	0.51%	0.22%	0.34%
Operating Expenses	$14.39M	$63.67M	$12.17M
YoY Change	18.29%	68.18%	42.16%
Operating Profit	$1.193M	$2.560M	-$6.565M
YoY Change	-118.17%	-113.65%	114.19%
Interest Expense	$0.00	$11.00K	$1.000K
YoY Change	-100.0%	37.5%
% of Operating Profit	0.0%	0.43%
Other Income/Expense, Net	$0.00	$14.00K	$0.00
YoY Change		-102.72%	-100.0%
Pretax Income	$1.190M	$2.574M	-$6.565M
YoY Change	-118.13%	-113.36%	101.69%
Income Tax	-$30.00K	$3.000K	-$1.059M
% Of Pretax Income	-2.52%	0.12%
Net Earnings	$1.220M	$2.571M	-$5.506M
YoY Change	-122.16%	-114.3%	69.16%
Net Earnings / Revenue	6.71%	3.88%	-98.32%
Basic Earnings Per Share	$0.08	$0.17	-$0.39
Diluted Earnings Per Share	$0.07	$0.16	-$0.39
COMMON SHARES
Basic Shares Outstanding	15.59M shares	15.25M shares	14.03M shares
Diluted Shares Outstanding		16.25M shares	14.03M shares

Balance Sheet

Concept	2015 Q4	2015	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$79.10M	$79.10M	$34.90M
YoY Change	126.65%	85.25%	249.0%
Cash & Equivalents	$79.08M	$79.10M	$34.87M
Short-Term Investments	$0.00	$0.00	$0.00
Other Short-Term Assets	$220.0K	$1.900M	$289.0K
YoY Change	-23.88%	11.76%	-27.75%
Inventory	$15.04M	$15.00M	$1.242M
Prepaid Expenses
Receivables	$26.27M	$26.30M	$11.96M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$122.3M	$122.3M	$49.71M
YoY Change	145.96%	130.75%	194.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.205M	$2.200M	$342.0K
YoY Change	544.74%	633.33%	-14.5%
Goodwill	$0.00
YoY Change
Intangibles	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$143.0K	$100.0K	$45.00K
YoY Change	217.78%		-93.57%
Total Long-Term Assets	$2.348M	$2.300M	$387.0K
YoY Change	506.72%	475.0%	-64.82%
TOTAL ASSETS
Total Short-Term Assets	$122.3M	$122.3M	$49.71M
Total Long-Term Assets	$2.348M	$2.300M	$387.0K
Total Assets	$124.6M	$124.6M	$50.09M
YoY Change	148.74%	133.33%	178.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.857M	$3.900M	$3.501M
YoY Change	10.17%	-4.88%	52.22%
Accrued Expenses	$24.41M	$23.90M	$12.17M
YoY Change	100.62%	146.39%	148.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$34.26M	$34.30M	$22.19M
YoY Change	54.43%	68.97%	28.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.26M	$34.30M	$22.19M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$34.30M	$34.30M	$22.20M
YoY Change	54.5%	68.97%	16.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$107.1M		-$109.7M
YoY Change	-2.34%
Common Stock	$15.00K		$14.00K
YoY Change	7.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00
YoY Change
Treasury Stock Shares	0.000 shares
Shareholders Equity	$90.34M	$90.30M	$27.91M
YoY Change
Total Liabilities & Shareholders Equity	$124.6M	$124.6M	$50.09M
YoY Change	148.74%	133.33%	178.3%

Cashflow Statement

Concept	2015 Q4	2015	2014 Q4
OPERATING ACTIVITIES
Net Income	$1.220M	$2.571M	-$5.506M
YoY Change	-122.16%	-114.3%	69.16%
Depreciation, Depletion And Amortization	$80.00K	$112.0K	$13.00K
YoY Change	515.38%	7.69%	-56.67%
Cash From Operating Activities	-$16.80M	-$9.718M	-$7.875M
YoY Change	113.33%	-29.8%	-39475.0%
INVESTING ACTIVITIES
Capital Expenditures	-$480.0K	$1.881M	$11.00K
YoY Change	-4463.64%	3989.13%	-210.0%
Acquisitions		$0.00	$0.00
YoY Change
Other Investing Activities	$24.00M	$0.00	$20.00M
YoY Change	20.0%	-100.0%
Cash From Investing Activities	$23.52M	-$1.881M	$19.99M
YoY Change	17.67%	-90.62%	-199980.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$54.33M	$0.00
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change
Cash From Financing Activities	380.0K	$55.81M	$34.00K
YoY Change	1017.65%	20.93%	-106.8%
NET CHANGE
Cash From Operating Activities	-16.80M	-$9.718M	-$7.875M
Cash From Investing Activities	23.52M	-$1.881M	$19.99M
Cash From Financing Activities	380.0K	$55.81M	$34.00K
Net Change In Cash	7.100M	$44.21M	$12.15M
YoY Change	-41.55%	260.46%	-2578.98%
FREE CASH FLOW
Cash From Operating Activities	-$16.80M	-$9.718M	-$7.875M
Capital Expenditures	-$480.0K	$1.881M	$11.00K
Free Cash Flow	-$16.32M	-$11.60M	-$7.886M
YoY Change	106.95%	-16.49%	-26386.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15636387	shares
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	739767440	USD
CY2015	dei	Entity Registrant Name EntityRegistrantName	Eagle Pharmaceuticals, Inc.
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	egrx	Accrued Ipo Costs AccruedIPOCosts	152000	USD
CY2014	egrx	Accrued Ipo Costs AccruedIPOCosts	0	USD
CY2014Q4	egrx	Accrued Ipo Costs AccruedIPOCosts	0	USD
CY2015	egrx	Accrued Ipo Costs AccruedIPOCosts	0	USD
CY2014Q4	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	839000	USD
CY2015Q4	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	9232000	USD
CY2014Q3	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	490000	USD
CY2014Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1307000	USD
CY2015Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1784000	USD
CY2014Q3	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1498000	USD
CY2013	egrx	Adjustments Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Noncash Interest Expense AdjustmentsNoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesNoncashInterestExpense	309000	USD
CY2014	egrx	Adjustments Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Noncash Interest Expense AdjustmentsNoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesNoncashInterestExpense	0	USD
CY2014Q4	egrx	Adjustments Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Noncash Interest Expense AdjustmentsNoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesNoncashInterestExpense	0	USD
CY2015	egrx	Adjustments Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Noncash Interest Expense AdjustmentsNoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesNoncashInterestExpense	0	USD
CY2012Q1	egrx	Asset Purchase Agreement Royalty On Net Profitsof Products Term AssetPurchaseAgreementRoyaltyOnNetProfitsofProductsTerm	P10Y
CY2015	egrx	Classof Warrantor Right Expected Term ClassofWarrantorRightExpectedTerm	P6Y
CY2015	egrx	Classof Warrantor Right Term Commencement Period After Closing Date ClassofWarrantorRightTermCommencementPeriodAfterClosingDate	P1Y
CY2008Q2	egrx	Collaborative Product Development Agreement Cumulative Milestones Upon Achievementof Goals CollaborativeProductDevelopmentAgreementCumulativeMilestonesUponAchievementofGoals	13000000	USD
CY2008Q2	egrx	Collaborative Product Development Agreement Monthly Receivable CollaborativeProductDevelopmentAgreementMonthlyReceivable	200000	USD
CY2008Q2	egrx	Collaborative Product Development Agreement Non Refundable Amount Receivedfor Signing CollaborativeProductDevelopmentAgreementNonRefundableAmountReceivedforSigning	750000	USD
CY2008Q2	egrx	Collaborative Product Development Agreement Paymentfor Product Development CollaborativeProductDevelopmentAgreementPaymentforProductDevelopment	2000000	USD
CY2013	egrx	Convertible Preferred Stock Forfeitures Dividends ConvertiblePreferredStockForfeituresDividends	3286000	USD
CY2013	egrx	Deferred Ipo Costs DeferredIPOCosts	-20000	USD
CY2014	egrx	Deferred Ipo Costs DeferredIPOCosts	0	USD
CY2014Q4	egrx	Deferred Ipo Costs DeferredIPOCosts	0	USD
CY2015	egrx	Deferred Ipo Costs DeferredIPOCosts	0	USD
CY2014Q4	egrx	Deferred Revenue Divestitureof Business Refund Dueto Insufficient Milestone Attainment DeferredRevenueDivestitureofBusinessRefundDuetoInsufficientMilestoneAttainment	6000000	USD
CY2015Q4	egrx	Deferred Revenue Divestitureof Business Refund Dueto Insufficient Milestone Attainment DeferredRevenueDivestitureofBusinessRefundDuetoInsufficientMilestoneAttainment	6000000	USD
CY2014Q3	egrx	Deferred Revenue Divestitureof Business Refund Dueto Insufficient Milestone Attainment DeferredRevenueDivestitureofBusinessRefundDuetoInsufficientMilestoneAttainment	6000000	USD
CY2014Q4	egrx	Deferred Tax Assets Accrued Vacation Pay DeferredTaxAssetsAccruedVacationPay	34000	USD
CY2015Q4	egrx	Deferred Tax Assets Accrued Vacation Pay DeferredTaxAssetsAccruedVacationPay	36000	USD
CY2013Q3	egrx	Deferred Tax Assets Accrued Vacation Pay DeferredTaxAssetsAccruedVacationPay	0	USD
CY2014Q3	egrx	Deferred Tax Assets Accrued Vacation Pay DeferredTaxAssetsAccruedVacationPay	54000	USD
CY2014Q4	egrx	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	12000	USD
CY2015Q4	egrx	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	12000	USD
CY2013Q3	egrx	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	161000	USD
CY2014Q3	egrx	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	0	USD
CY2014Q4	egrx	Deferred Tax Assets In Process Researchand Development Credit DeferredTaxAssetsInProcessResearchandDevelopmentCredit	2790000	USD
CY2015Q4	egrx	Deferred Tax Assets In Process Researchand Development Credit DeferredTaxAssetsInProcessResearchandDevelopmentCredit	2790000	USD
CY2013Q3	egrx	Deferred Tax Assets In Process Researchand Development Credit DeferredTaxAssetsInProcessResearchandDevelopmentCredit	2033000	USD
CY2014Q3	egrx	Deferred Tax Assets In Process Researchand Development Credit DeferredTaxAssetsInProcessResearchandDevelopmentCredit	1886000	USD
CY2014Q4	egrx	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	0	USD
CY2015Q4	egrx	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	0	USD
CY2013Q3	egrx	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	0	USD
CY2014Q3	egrx	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	5000	USD
CY2013	egrx	Depreciationand Amortization Expense Excluding Amortizationof Financing Costsand Debt Discount Premium DepreciationandAmortizationExpenseExcludingAmortizationofFinancingCostsandDebtDiscountPremium	135000	USD
CY2014	egrx	Depreciationand Amortization Expense Excluding Amortizationof Financing Costsand Debt Discount Premium DepreciationandAmortizationExpenseExcludingAmortizationofFinancingCostsandDebtDiscountPremium	104000	USD
CY2014Q4	egrx	Depreciationand Amortization Expense Excluding Amortizationof Financing Costsand Debt Discount Premium DepreciationandAmortizationExpenseExcludingAmortizationofFinancingCostsandDebtDiscountPremium	13000	USD
CY2015	egrx	Depreciationand Amortization Expense Excluding Amortizationof Financing Costsand Debt Discount Premium DepreciationandAmortizationExpenseExcludingAmortizationofFinancingCostsandDebtDiscountPremium	112000	USD
CY2013	egrx	Effective Income Tax Rate Reconciliation Fair Value Adjustmentof Warrants Non Cash Interest EffectiveIncomeTaxRateReconciliationFairValueAdjustmentofWarrantsNonCashInterest	0.1382
CY2014	egrx	Effective Income Tax Rate Reconciliation Fair Value Adjustmentof Warrants Non Cash Interest EffectiveIncomeTaxRateReconciliationFairValueAdjustmentofWarrantsNonCashInterest	0.0107
CY2014Q4	egrx	Effective Income Tax Rate Reconciliation Fair Value Adjustmentof Warrants Non Cash Interest EffectiveIncomeTaxRateReconciliationFairValueAdjustmentofWarrantsNonCashInterest	-0.0001
CY2015	egrx	Effective Income Tax Rate Reconciliation Fair Value Adjustmentof Warrants Non Cash Interest EffectiveIncomeTaxRateReconciliationFairValueAdjustmentofWarrantsNonCashInterest	0.0000
CY2012Q1	egrx	Expected Cash Proceeds Upon Regulatory Approval Milestone ExpectedCashProceedsUponRegulatoryApprovalMilestone	1000000	USD
CY2015Q4	egrx	Expected Cash Proceedson Additional Milestones Dependenton Licensor Sales Activity ExpectedCashProceedsonAdditionalMilestonesDependentonLicensorSalesActivity	3000000	USD
CY2013	egrx	Income Taxes Paid Franchise Taxes Paid IncomeTaxesPaidFranchiseTaxesPaid	20000	USD
CY2014	egrx	Income Taxes Paid Franchise Taxes Paid IncomeTaxesPaidFranchiseTaxesPaid	9000	USD
CY2014Q4	egrx	Income Taxes Paid Franchise Taxes Paid IncomeTaxesPaidFranchiseTaxesPaid	0	USD
CY2015	egrx	Income Taxes Paid Franchise Taxes Paid IncomeTaxesPaidFranchiseTaxesPaid	91000	USD
CY2013	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	1368000	USD
CY2014	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-192000	USD
CY2014Q4	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-71000	USD
CY2015	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	225000	USD
CY2015	egrx	Marketing Rights Term MarketingRightsTerm	P10Y
CY2012Q1	egrx	Milestonereductionfor Regulatory Approvalof Generic Competitor Minimum MilestonereductionforRegulatoryApprovalofGenericCompetitorMinimum	500000	USD
CY2013	egrx	Noncash Operating Activity Deferred Rent NoncashOperatingActivityDeferredRent	0	USD
CY2014	egrx	Noncash Operating Activity Deferred Rent NoncashOperatingActivityDeferredRent	0	USD
CY2014Q4	egrx	Noncash Operating Activity Deferred Rent NoncashOperatingActivityDeferredRent	0	USD
CY2015	egrx	Noncash Operating Activity Deferred Rent NoncashOperatingActivityDeferredRent	367000	USD
CY2015Q4	egrx	Number Of Products NumberOfProducts	5	product
CY2013	egrx	Operating Loss Carryforwards Sales OperatingLossCarryforwardsSales	11029000	USD
CY2014	egrx	Operating Loss Carryforwards Sales OperatingLossCarryforwardsSales	25389000	USD
CY2014Q4	egrx	Operating Loss Carryforwards Sales OperatingLossCarryforwardsSales	12588000	USD
CY2014Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	148000	USD
CY2015Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	551000	USD
CY2014Q3	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	197000	USD
CY2014Q4	egrx	Prepaid Product Costs PrepaidProductCosts	1020000	USD
CY2015Q4	egrx	Prepaid Product Costs PrepaidProductCosts	85000	USD
CY2014Q3	egrx	Prepaid Product Costs PrepaidProductCosts	840000	USD
CY2014Q4	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	0	USD
CY2015Q4	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	283000	USD
CY2014Q3	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	0	USD
CY2015	egrx	Product Development Agreements Exclusive Rights Acquired Numberof Products ProductDevelopmentAgreementsExclusiveRightsAcquiredNumberofProducts	33	product
CY2015	egrx	Royalty Revenue Commercial Partners Obligationof Sales Report Term RoyaltyRevenueCommercialPartnersObligationofSalesReportTerm	P60D
CY2015	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercised Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedIntrinsicValue	10815000	USD
CY2014Q4	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	710486	shares
CY2015Q4	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	1176140	shares
CY2013Q3	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	302603	shares
CY2014Q3	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	712901	shares
CY2014Q1	egrx	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	1788	shares
CY2014Q1	egrx	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	1788	shares
CY2014	egrx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	21000	USD
CY2013	egrx	Tax Credit Carryforwardsales TaxCreditCarryforwardsales	95000	USD
CY2014	egrx	Tax Credit Carryforwardsales TaxCreditCarryforwardsales	177000	USD
CY2014Q4	egrx	Tax Credit Carryforwardsales TaxCreditCarryforwardsales	15000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3501000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3857000	USD
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4059000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11956000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26267000	USD
CY2014Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7296000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12165000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24405000	USD
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9671000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	502000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	792000	USD
CY2014Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	591000	USD
CY2014Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1025000	USD
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2242000	USD
CY2014Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	890000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	794000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	865000	USD
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	780000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137577000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	197440000	USD
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137259000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	0	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	317000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	606000	USD
CY2014Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	284000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4051000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	317000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	606000	USD
CY2014Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	284000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4051000	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1091000	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2014Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	96000	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2014Q4	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8448711	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3871141	shares
CY2014Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1302685	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	96610	shares
CY2014Q4	us-gaap	Assets Assets	50094000	USD
CY2015Q4	us-gaap	Assets Assets	124605000	USD
CY2014Q3	us-gaap	Assets Assets	53411000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	49707000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	122257000	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	53022000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34869000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79083000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5067000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10456000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22722000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5389000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	12266000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	12147000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	44214000	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2876702	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14036680	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15636387	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14032167	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14036680	shares
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	14000	USD
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	7381000	USD
CY2013Q4	us-gaap	Cost Of Revenue CostOfRevenue	4624000	USD
CY2014	us-gaap	Cost Of Revenue CostOfRevenue	11714000	USD
CY2014Q4	us-gaap	Cost Of Revenue CostOfRevenue	4489000	USD
CY2015	us-gaap	Cost Of Revenue CostOfRevenue	15647000	USD
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15636387	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14032167	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	14000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000	USD
CY2014Q4	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3000	USD
CY2013	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	10062000	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2014Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2014Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	73000	USD
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	88000	USD
CY2013Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	47000	USD
CY2014Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	143000	USD
CY2014Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	0	USD
CY2015Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	521000	USD
CY2014Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	0	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6520000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6000000	USD
CY2014Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6585000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	71000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	64000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	28000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	80000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	208000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	USD
CY2013Q3	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	208000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	234000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	33000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	26000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	39000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	34000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40252000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	38606000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	32817000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	38389000	USD
CY2014Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2264000	USD
CY2015Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1884000	USD
CY2013Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2573000	USD
CY2014Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2354000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	40179000	USD
CY2014Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	112000	USD
CY2013	us-gaap	Dividends Preferred Stock DividendsPreferredStock	3837000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	38518000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	32770000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	38246000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33286000	USD
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.44
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30837000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26984000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32527000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	68000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	57000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	77000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	70000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	309000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	705000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	0	USD
CY2014Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	204000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	109000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	0	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	0	USD
CY2014Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1057000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2100000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	688000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	944000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	93000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	0	USD
CY2014Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	0	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	24000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40179000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38518000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	32770000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38246000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	7000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	7000	USD
CY2013Q3	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2014Q3	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	66000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	81000	USD
CY2013Q3	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	47000	USD
CY2014Q3	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	138000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	135000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	104000	USD
CY2014	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1666000	USD
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.25
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0514
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0062
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.97
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.38
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.17
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.44
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.25
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.44
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.97
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.31
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.1294
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0672
CY2014Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.1918
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0012
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.3400
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.3400
CY2014Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.3400
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2511
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.3225
CY2014Q4	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.3125
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2515
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Meals And Entertainment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment	0.0000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Meals And Entertainment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment	0.0000
CY2014Q4	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Meals And Entertainment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment	0.0008
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Meals And Entertainment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment	0.0091
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0022
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0006
CY2014Q4	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.1295
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0672
CY2014Q4	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.1918
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0012
CY2014Q4	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0268
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0976
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8287000	USD
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1052000	USD
CY2013Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	191000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	573000	USD
CY2014Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2013	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014Q4	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-273000	USD
CY2013	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	4050000	USD
CY2014	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2014Q4	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2015	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6947000	USD
CY2013Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3255000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19272000	USD
CY2014Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6565000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2574000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-899000	USD
CY2013Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1295000	USD
CY2014Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1059000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014Q4	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	482000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-251000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2867000	USD
CY2014Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-558000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	356000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3543000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2172000	USD
CY2014Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4660000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14311000	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1694000	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6692000	USD
CY2014Q4	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2494000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	11873000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	520000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3435000	USD
CY2014Q4	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-65000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-520000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-87000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1294000	USD
CY2014Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-52000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13800000	USD
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-30000	USD
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1000	USD
CY2014Q4	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	98000	USD
CY2015Q4	us-gaap	Increase In Unrecognized Tax Benefits Is Reasonably Possible IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	10300000	USD
CY2013	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2014Q4	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1003627	shares
CY2013	us-gaap	Interest Expense InterestExpense	309000	USD
CY2013Q4	us-gaap	Interest Expense InterestExpense	0	USD
CY2014	us-gaap	Interest Expense InterestExpense	8000	USD
CY2014Q4	us-gaap	Interest Expense InterestExpense	1000	USD
CY2015	us-gaap	Interest Expense InterestExpense	11000	USD
CY2013	us-gaap	Interest Expense Debt InterestExpenseDebt	545000	USD
CY2014Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2014Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2015	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2013	us-gaap	Interest Paid InterestPaid	0	USD
CY2014	us-gaap	Interest Paid InterestPaid	8000	USD
CY2014Q4	us-gaap	Interest Paid InterestPaid	1000	USD
CY2015	us-gaap	Interest Paid InterestPaid	11000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1242000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	311000	USD
CY2014Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1294000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	1242000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	15042000	USD
CY2014Q3	us-gaap	Inventory Net InventoryNet	1294000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	8687000	USD
CY2014Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	6044000	USD
CY2014Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	USD
CY2013Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	31000	USD
CY2014Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	25000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	314000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	277000	USD
CY2014Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	68000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	22134000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	514000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50094000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	124605000	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53411000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22186000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34262000	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	20315000	USD
CY2013Q4	us-gaap	Loss Contingency Patents Allegedly Infringed Number LossContingencyPatentsAllegedlyInfringedNumber	1	patent
CY2013	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	0	USD
CY2014	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2506000	USD
CY2014Q4	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1556000	USD
CY2015	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	4752000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9809000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46154000	USD
CY2014Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55813000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1459000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20045000	USD
CY2014Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19988000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1881000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5879000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13843000	USD
CY2014Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7875000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9718000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-6048000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-3255000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-17977000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-5506000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	2571000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9885000	USD
CY2013Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4387000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3218000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2934000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9104000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19643000	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5506000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	19697000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8177000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10167000	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1218000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2571000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1508000	USD
CY2013Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-190000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-515000	USD
CY2014Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1000	USD
CY2014Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14000	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	8557000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	37856000	USD
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	12165000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	63667000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-8455000	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-3065000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3603000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2982000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9107000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-18757000	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-6565000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	20090000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8335000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10388000	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	1193000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	2560000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2488000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	515000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	281000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	564000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	564000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	564000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	304000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	USD
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	445000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	289000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	220000	USD
CY2014Q3	us-gaap	Other Assets Current OtherAssetsCurrent	329000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	143000	USD
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35000	USD
CY2014Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2013	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2014	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	3765000	USD
CY2014Q4	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2015	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	45000000	USD
CY2013	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	20000	USD
CY2014	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2014Q4	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2015	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2013	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46000	USD
CY2014Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1881000	USD
CY2013	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2014	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	19999000	USD
CY2014Q4	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2015	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	105999000	USD
CY2015	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.06
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1640000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1865000	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1711000	USD
CY2014Q4	us-gaap	Prepaid Insurance PrepaidInsurance	183000	USD
CY2015Q4	us-gaap	Prepaid Insurance PrepaidInsurance	218000	USD
CY2014Q3	us-gaap	Prepaid Insurance PrepaidInsurance	345000	USD
CY2014Q4	us-gaap	Prepaid Taxes PrepaidTaxes	0	USD
CY2015Q4	us-gaap	Prepaid Taxes PrepaidTaxes	508000	USD
CY2014Q3	us-gaap	Prepaid Taxes PrepaidTaxes	0	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	6500000	USD
CY2013	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	46069000	USD
CY2014	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	46069000	USD
CY2014Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2015	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	54331000	USD
CY2013	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	9829000	USD
CY2014	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2014Q4	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2013	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	1500000	USD
CY2014	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	USD
CY2014Q4	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	19999000	USD
CY2015	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	105999000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	65000	USD
CY2014Q4	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	34000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1482000	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2014Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	21000	USD
CY2014Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	21000	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	21000	USD
CY2014Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2013Q2	us-gaap	Professional Fees ProfessionalFees	1993000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1136000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3070000	USD
CY2014Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1124000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	342000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2205000	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	344000	USD
CY2015Q4	us-gaap	Purchase Obligation PurchaseObligation	6879000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9795000	USD
CY2013Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2589000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16816000	USD
CY2014Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3986000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27855000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109683000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107112000	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104177000	USD
CY2013	us-gaap	Royalty Revenue RoyaltyRevenue	8364000	USD
CY2013Q4	us-gaap	Royalty Revenue RoyaltyRevenue	3268000	USD
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	10708000	USD
CY2014Q4	us-gaap	Royalty Revenue RoyaltyRevenue	4094000	USD
CY2015	us-gaap	Royalty Revenue RoyaltyRevenue	8259000	USD
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	5315000	USD
CY2013Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2224000	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4626000	USD
CY2014Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1506000	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	12968000	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	13679000	USD
CY2013Q4	us-gaap	Sales Revenue Net SalesRevenueNet	5492000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	5005000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	5792000	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	2810000	USD
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	19099000	USD
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	5600000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	36309000	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1308993	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.29
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.16
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.58
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.16
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	611684	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	668702	shares
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	6002000	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	5736000	USD
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	18180000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	66227000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4958000	USD
CY2013Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1344000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9326000	USD
CY2014Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3690000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20165000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	317000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	606000	USD
CY2014Q4	us-gaap	Share Based Compensation ShareBasedCompensation	284000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	4051000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.64
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3945
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.64
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.329
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.3364
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.284
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0253
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0216
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0216
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0209
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0095
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0177
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0211
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0142
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	50931	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	11310	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	39596	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	558699	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	29000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	773458	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.73
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.61
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.73
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.92
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9600000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	54700000	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	200	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5900000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1322170	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1844842	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	813259	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	510656	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	596092	shares
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.34
CY2014Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.62
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.06
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.72
CY2014Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.61
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	48.65
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2014Q3	us-gaap	Short Term Investments ShortTermInvestments	19999000	USD
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	12034	shares
CY2014Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4513	shares
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	211190	shares
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	46048000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	54331000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	65000	USD
CY2014Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	34000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1482000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	27908000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	90343000	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	-93433000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	-87929000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	33096000	USD
CY2013	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	3837000	USD
CY2013Q4	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	1132000	USD
CY2014	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	1666000	USD
CY2014Q4	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2015	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-1661000	USD
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3044308	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9955937	shares
CY2014Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14032828	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16253781	shares
CY2013Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3048131	shares
CY2014Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14032828	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3044308	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9955937	shares
CY2014Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14032828	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15250154	shares
CY2015	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation</font></div></div>
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000827871-16-000049-index-headers.html	Edgar Link	pending
0000827871-16-000049-index.html	Edgar Link	pending
0000827871-16-000049.txt	Edgar Link	pending
0000827871-16-000049-xbrl.zip	Edgar Link	pending
bdo.jpg	Edgar Link	pending
bdosig.jpg	Edgar Link	pending
egrx-20151231.xml	Edgar Link	completed
egrx-20151231.xsd	Edgar Link	pending
egrx-20151231_cal.xml	Edgar Link	unprocessable
egrx-20151231_def.xml	Edgar Link	unprocessable
egrx-20151231_lab.xml	Edgar Link	unprocessable
egrx-20151231_pre.xml	Edgar Link	unprocessable
egrx_10kx2015.htm	Edgar Link	pending
egrx_10kx2015xchart-23220.jpg	Edgar Link	pending
exhibit102310k2015.htm	Edgar Link	pending
exhibit102410k2015.htm	Edgar Link	pending
exhibit23110k2015.htm	Edgar Link	pending
exhibit31110k2015.htm	Edgar Link	pending
exhibit31210k2015.htm	Edgar Link	pending
exhibit32110k2015.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2015 Q4 Form 10-K Financial Statement

#000082787116000049 Filed on February 29, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2015 Q4 Form 10-K Financial Statement

#000082787116000049 Filed on February 29, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx